意大利的过敏原免疫疗法:如何,何时,为什么-通过患者协会进行的现实研究
Giovanni Paoletti1,2, Emanuele Nappi2, Maria Chiara Bragato2
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
The World Allergy Organization journal
|January 15, 2025
概括
过敏原免疫疗法 (AIT) 由于意识低和成本障碍,尽管改善了患者的生活质量,但仍未得到充分利用. 增加AIT的可访问性和教育对于有效管理过敏至关重要.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 公共卫生 公共卫生
- 患者倡导 患者倡导
背景情况:
- 过敏原免疫疗法 (AIT) 是对过敏的唯一疾病修饰治疗方法,但未得到充分使用.
- 关于AIT使用模式和促成因素的研究有限.
- 了解这些模式可以为策略提供信息,以增加AIT在人口层面的影响.
研究的目的:
- 评估意大利AIT使用趋势.
- 评估患者对AIT的健康素养.
- 了解过敏和AIT对患者生活的影响.
主要方法:
- 一份问卷分发给与Respiriamo Insieme APS患者协会关联的患者.
- 数据收集发生在2023年5月至10月之间.
- 该调查评估了AIT的认识,提议,启动,坚持以及感知到的有效性/安全性.
主要成果:
- 只有53.8%的患者知道AIT;它被建议给33.1%的过敏鼻炎/喘患者.
- 拒绝的原因包括不决心 (26.5%),成本 (22.9%) 和怀疑 (19.3%).
- 完成AIT的患者报告说,失去了工作/上学日数显著减少,并发现它有效和安全.
结论:
- 关于AIT的重大错误信息需要改进宣传活动.
- 完成AIT导致缺勤率降低和患者报告的积极结果.
- 建议倡导经济可访问性和国家可退还性标准化.
相关概念视频
02:06Allergic Reactions
27.2K
Overview
27.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236